27.02.09

Savene/Totect Reaches Profitability for TopoTarget

Sales of Savene/Totect close to being doubled from 2007 to 2008.

TopoTarget has announced that sales of their products; Savene in Europe and Totect in the US for the treatment of anthracyclin extravasation accidents, is now trading profitably in both continents. TopoTarget has succeeded in gaining close to a doubling of sales and at the same time streamlining their activities. The total sales in 2008 amounted to DKK 39.1 mio. against DKK 21.6 mio. in 2007. Savene/Totect has now become a profitable and attractive business and TopoTarget believe the product will be an important contributor to their activities in the future.

- I'm very proud on behalf of TopoTarget that the sales of Savene/Totect are now in black numbers, says Professor Peter Buhl Jensen, CEO of TopoTarget.

Source: Press release, TopoTarget, 26.02.09